JP5416327B2 - タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 - Google Patents
タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 Download PDFInfo
- Publication number
- JP5416327B2 JP5416327B2 JP2004500859A JP2004500859A JP5416327B2 JP 5416327 B2 JP5416327 B2 JP 5416327B2 JP 2004500859 A JP2004500859 A JP 2004500859A JP 2004500859 A JP2004500859 A JP 2004500859A JP 5416327 B2 JP5416327 B2 JP 5416327B2
- Authority
- JP
- Japan
- Prior art keywords
- antitumor agent
- cancer
- taxane
- agent
- taxane antitumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940123237 Taxane Drugs 0.000 title claims abstract description 273
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims abstract description 254
- 239000003814 drug Substances 0.000 title claims abstract description 120
- 229940079593 drug Drugs 0.000 title claims abstract description 115
- 206010029350 Neurotoxicity Diseases 0.000 title claims description 54
- 206010044221 Toxic encephalopathy Diseases 0.000 title claims description 54
- 231100000228 neurotoxicity Toxicity 0.000 title claims description 54
- 230000007135 neurotoxicity Effects 0.000 title claims description 54
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 297
- 238000011282 treatment Methods 0.000 claims abstract description 152
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 56
- 201000011510 cancer Diseases 0.000 claims abstract description 55
- 229940034982 antineoplastic agent Drugs 0.000 claims abstract description 3
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 claims description 80
- 150000003057 platinum Chemical class 0.000 claims description 57
- 229960004316 cisplatin Drugs 0.000 claims description 53
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 52
- 229930012538 Paclitaxel Natural products 0.000 claims description 50
- 229960001592 paclitaxel Drugs 0.000 claims description 50
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 50
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 48
- 239000000126 substance Substances 0.000 claims description 45
- 230000035807 sensation Effects 0.000 claims description 42
- 239000003223 protective agent Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 39
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 38
- 208000002193 Pain Diseases 0.000 claims description 37
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 37
- 231100000862 numbness Toxicity 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 206010040021 Sensory abnormalities Diseases 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 28
- 230000002093 peripheral effect Effects 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 25
- 230000001988 toxicity Effects 0.000 claims description 23
- 231100000419 toxicity Toxicity 0.000 claims description 23
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 20
- 229960004562 carboplatin Drugs 0.000 claims description 20
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 18
- 238000004904 shortening Methods 0.000 claims description 18
- 230000002159 abnormal effect Effects 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 230000036407 pain Effects 0.000 claims description 17
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 16
- 208000034783 hypoesthesia Diseases 0.000 claims description 16
- 201000005202 lung cancer Diseases 0.000 claims description 16
- 208000020816 lung neoplasm Diseases 0.000 claims description 16
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 15
- 208000006820 Arthralgia Diseases 0.000 claims description 14
- 206010004593 Bile duct cancer Diseases 0.000 claims description 14
- 206010005003 Bladder cancer Diseases 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 14
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 14
- 206010033799 Paralysis Diseases 0.000 claims description 14
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 14
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 14
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 14
- 201000004101 esophageal cancer Diseases 0.000 claims description 14
- 235000013372 meat Nutrition 0.000 claims description 14
- 210000003205 muscle Anatomy 0.000 claims description 14
- 229960001756 oxaliplatin Drugs 0.000 claims description 14
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 14
- 230000001953 sensory effect Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 11
- 208000020764 Sensation disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000004044 Hypesthesia Diseases 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 208000035824 paresthesia Diseases 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 229940124444 chemoprotective agent Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 13
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 13
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 13
- 230000006735 deficit Effects 0.000 claims 10
- 239000009321 antitumor A Substances 0.000 claims 5
- 208000036119 Frailty Diseases 0.000 claims 3
- 206010003549 asthenia Diseases 0.000 claims 3
- CETBSQOFQKLHHZ-UHFFFAOYSA-N Diethyl disulfide Chemical compound CCSSCC CETBSQOFQKLHHZ-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000004224 protection Effects 0.000 claims 1
- 239000011814 protection agent Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 abstract description 31
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 5
- 230000002411 adverse Effects 0.000 abstract description 5
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 230000036571 hydration Effects 0.000 description 17
- 238000006703 hydration reaction Methods 0.000 description 17
- 230000000259 anti-tumor effect Effects 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 14
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 10
- 229960003668 docetaxel Drugs 0.000 description 10
- 238000011269 treatment regimen Methods 0.000 description 10
- 238000011260 co-administration Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 8
- 239000000654 additive Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 208000019430 Motor disease Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000012910 preclinical development Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 229950009278 dimesna Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940108949 paclitaxel injection Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940090016 tegretol Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/135,975 US8710095B2 (en) | 2002-04-30 | 2002-04-30 | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US10/135,975 | 2002-04-30 | ||
| PCT/US2003/013518 WO2003092675A1 (en) | 2002-04-30 | 2003-04-29 | Drugs for mitigating taxane-induced neurotoxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011089619A Division JP2011140521A (ja) | 2002-04-30 | 2011-04-13 | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005525409A JP2005525409A (ja) | 2005-08-25 |
| JP2005525409A5 JP2005525409A5 (https=) | 2008-08-21 |
| JP5416327B2 true JP5416327B2 (ja) | 2014-02-12 |
Family
ID=29249584
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500859A Expired - Fee Related JP5416327B2 (ja) | 2002-04-30 | 2003-04-29 | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 |
| JP2011089619A Pending JP2011140521A (ja) | 2002-04-30 | 2011-04-13 | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011089619A Pending JP2011140521A (ja) | 2002-04-30 | 2011-04-13 | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8710095B2 (https=) |
| EP (1) | EP1503748B1 (https=) |
| JP (2) | JP5416327B2 (https=) |
| AT (1) | ATE554753T1 (https=) |
| AU (1) | AU2003225253B2 (https=) |
| CA (1) | CA2483857A1 (https=) |
| ES (1) | ES2381968T3 (https=) |
| WO (1) | WO2003092675A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20090111735A1 (en) * | 2004-05-12 | 2009-04-30 | Bionumerik Pharmaceuticals, Inc. | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| EP1991237B1 (en) * | 2005-12-13 | 2015-02-25 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| EP2004175A4 (en) * | 2006-03-16 | 2010-12-15 | Bionumerik Pharmaceuticals Inc | COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE |
| CN101790377A (zh) * | 2007-08-31 | 2010-07-28 | 国立大学法人九州大学 | 抗癌剂导致的末梢神经障碍的预防或减轻剂 |
| CA2706378C (en) | 2007-11-20 | 2017-09-12 | Lankenau Institute For Medical Research | Disulfide chemotherapeutic agents and methods of use thereof |
| ES2476602T3 (es) * | 2008-03-14 | 2014-07-15 | Bionumerik Pharmaceuticals, Inc. | Composiciones y métodos quimioprotectores |
| CN102014891B (zh) * | 2008-03-14 | 2013-12-18 | 比奥纽默里克药物公司 | 增加癌症患者存活时间的化合物的组合物和使用方法 |
| CA2717181C (en) * | 2008-03-14 | 2013-10-15 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| US9320760B2 (en) * | 2008-03-14 | 2016-04-26 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| US20090232906A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| UY33203A (es) | 2010-01-27 | 2011-08-31 | Takeda Pharmaceutical | Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno |
| US11471431B2 (en) * | 2010-09-16 | 2022-10-18 | Lantern Pharma Inc. | Increasing cancer patient survival time by administration of dithio-containing compounds |
| WO2015070323A1 (en) * | 2013-11-15 | 2015-05-21 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
| KR102607967B1 (ko) * | 2016-12-19 | 2023-11-29 | 메르크 파텐트 게엠베하 | 단백질 키나제 억제제 및 추가 화학요법제의 조합물 |
| CA3060266A1 (en) | 2017-04-17 | 2018-10-25 | Indiana University Research And Technology Corporation | Prevention and reversal of inflammation induced dna damage |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993010076A1 (en) * | 1991-11-22 | 1993-05-27 | The University Of Mississippi | Synthesis and optical resolution of the taxol side chain and related compounds |
| FR2722987B1 (fr) * | 1994-07-29 | 1997-05-16 | Synthelabo | Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux |
| US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5789000A (en) | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| DE19617802A1 (de) | 1996-05-03 | 1997-11-06 | Basf Ag | Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen |
| ES2170414T3 (es) | 1996-09-23 | 2002-08-01 | Bionumerik Pharmaceuticals Inc | Reduccion de efectos toxicos del carboplatino usando ditioeteres. |
| US6037336A (en) | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| CN1082047C (zh) | 1996-10-01 | 2002-04-03 | 比奥纽默里克药物公司 | 生产巯基链烷磺酸盐和磷酸盐及其衍生物的方法 |
| US6160167A (en) | 1998-04-21 | 2000-12-12 | Bionumerik Pharmaceuticals, Inc. | Mercaptans and disulfides |
| US6172119B1 (en) | 1999-02-09 | 2001-01-09 | Bionumerik Pharmaceuticals, Inc. | Method of treating acute renal failure |
| US5998479A (en) | 1999-02-09 | 1999-12-07 | Bionumerik Pharmaceuticals, Inc. | Method of treating adult respiratory syndrome |
| US6177411B1 (en) | 1999-02-09 | 2001-01-23 | Bionumerik Pharmaceuticals, Inc. | Method for treating heavy metal poisoning |
| US6197831B1 (en) | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
| US6075053A (en) | 1999-02-09 | 2000-06-13 | Bionumerik Pharmaceuticals, Inc. | Method of reducing or reversing neuropathy |
| US6034126A (en) | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
| US6077838A (en) | 1999-06-08 | 2000-06-20 | Bionumerik Pharmaceuticals, Inc. | Method of treating hangover |
| US6143796A (en) | 1999-09-02 | 2000-11-07 | Bionumerik Pharmaceuticals, Inc. | Method for reducing development of free radical induced malignancies |
| US6468993B1 (en) | 1999-10-04 | 2002-10-22 | Bionumerik Pharmaceuticals, Inc. | Method for reducing development of osteoporosis |
| US6251881B1 (en) | 1999-10-21 | 2001-06-26 | Frederick H. Hausheer | Method of treating diabetic angiopathy |
| US6043274A (en) | 1999-10-21 | 2000-03-28 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic cardiomyopathy |
| US6031006A (en) | 1999-10-21 | 2000-02-29 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic nephropathy |
| US6100247A (en) | 1999-10-21 | 2000-08-08 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic neuropathy |
| US6274622B1 (en) | 1999-10-27 | 2001-08-14 | Frederick H. Hausheer | Method of treating diabetic ophthalmopathy |
| US6525037B1 (en) | 2000-02-25 | 2003-02-25 | Bionumerik Pharmaceuticals, Inc. | Method of treating atherosclerosis and complications resulting therefrom |
| AU2000239101A1 (en) * | 2000-03-22 | 2001-10-03 | Neopharm, Inc. | A method of administering liposomal encapsulated taxane |
| US6245815B1 (en) | 2000-04-15 | 2001-06-12 | Bionumerik Pharmaceuticals, Inc. | Method of treating alcoholism and complications resulting therefrom |
| US6468963B1 (en) | 2000-05-01 | 2002-10-22 | Bionumerik Pharmaceuticals, Inc. | Methods and formulations for reducing toxicity associated with diabetes treatments |
| FR2811987A1 (fr) | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
| US6225295B1 (en) | 2000-09-27 | 2001-05-01 | Frederick H. Hausheer | Method of treating acetaminophen overdose |
| US6291441B1 (en) | 2000-09-27 | 2001-09-18 | Frederick H. Hausheer | Method of treating inflammatory bowel disorders |
| US6255355B1 (en) | 2001-01-06 | 2001-07-03 | Seetharamulu Peddaiahgari | Method of inhibiting angiogenesis |
| EP1351677A4 (en) | 2001-01-19 | 2009-08-19 | Bionumerik Pharmaceuticals Inc | CANCER TREATMENT METHOD |
| US6352979B1 (en) | 2001-08-20 | 2002-03-05 | Lucinda Lizcano | Method of treating snakebite and complications resulting therefrom |
| US7176192B2 (en) | 2001-10-26 | 2007-02-13 | Bionumerik Pharmaceuticals, Inc. | Method for treating patients for radiation exposure |
| US6596320B1 (en) | 2002-01-11 | 2003-07-22 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer having greater efficacy and reduced adverse effects |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US6504049B1 (en) | 2002-04-30 | 2003-01-07 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing pharmaceutically active disulfide salts |
| US20040014730A1 (en) | 2002-07-10 | 2004-01-22 | Frederick Hausheer | Formulations and methods of reducing toxicity of anti-infective agents |
| MXPA05006721A (es) | 2002-12-21 | 2005-09-30 | Bionumerik Pharmaceuticals Inc | Metodo para tratamiento de pacientes expuestos a agentes quimicos toxicos. |
| US20040152774A1 (en) | 2003-02-04 | 2004-08-05 | Hausheer Frederick H. | Method of protecing against tissue extra vasation injury |
| CA2548497C (en) | 2003-12-17 | 2009-06-09 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing disulfides |
-
2002
- 2002-04-30 US US10/135,975 patent/US8710095B2/en not_active Expired - Fee Related
-
2003
- 2003-04-29 ES ES03721972T patent/ES2381968T3/es not_active Expired - Lifetime
- 2003-04-29 WO PCT/US2003/013518 patent/WO2003092675A1/en not_active Ceased
- 2003-04-29 EP EP03721972A patent/EP1503748B1/en not_active Expired - Lifetime
- 2003-04-29 AU AU2003225253A patent/AU2003225253B2/en not_active Ceased
- 2003-04-29 CA CA002483857A patent/CA2483857A1/en not_active Abandoned
- 2003-04-29 JP JP2004500859A patent/JP5416327B2/ja not_active Expired - Fee Related
- 2003-04-29 AT AT03721972T patent/ATE554753T1/de active
-
2011
- 2011-04-13 JP JP2011089619A patent/JP2011140521A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1503748B1 (en) | 2012-04-25 |
| ATE554753T1 (de) | 2012-05-15 |
| AU2003225253A1 (en) | 2003-11-17 |
| US20030203960A1 (en) | 2003-10-30 |
| WO2003092675A1 (en) | 2003-11-13 |
| CA2483857A1 (en) | 2003-11-13 |
| JP2011140521A (ja) | 2011-07-21 |
| US8710095B2 (en) | 2014-04-29 |
| AU2003225253B2 (en) | 2008-09-04 |
| EP1503748A1 (en) | 2005-02-09 |
| EP1503748A4 (en) | 2009-10-21 |
| JP2005525409A (ja) | 2005-08-25 |
| ES2381968T3 (es) | 2012-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| USRE45105E1 (en) | Method of treating cancer by co-administration of anticancer agents | |
| RU2662298C2 (ru) | Лечение рака комбинацией плинабулина и таксана | |
| WO2000018393A1 (en) | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin | |
| JP7193591B2 (ja) | 化学療法の改善 | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| JP2005525409A5 (https=) | ||
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| KR20020060226A (ko) | 배합 화학요법 | |
| KR20040078123A (ko) | 에포틸론 및 대사길항물질을 포함하는 조합물 | |
| EP1273296B1 (en) | Combination of acetyldinaline and docetaxel | |
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| KR20150136073A (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| JP2013510866A (ja) | 組み合わせたチボザニブおよびテムシロリムス | |
| EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
| CN119816307A (zh) | 包含flt3抑制剂的癌症组合疗法 | |
| US20030134893A1 (en) | Combination chemotherapy | |
| WO2004073719A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
| HK1072723B (en) | Combinations comprising an epothilone derivatives and an imidazotetrazinone | |
| KR20110104932A (ko) | Ａｖｅ８０６２ 및 도세탁셀이 조합된 항종양 조합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080620 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100119 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100225 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100716 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110413 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110509 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20110812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121212 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121218 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130207 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130910 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5416327 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |